Talisman

A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity

Near Add Your Location

Sorting 8 by

Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
Duke Cancer Center
Duke University Medical Center
Durham, NC
  • Accepting patients
University Hospitals Seidman Cancer Center
Seidman Cancer Center at UH Case Medical
Cleveland, OH
  • Accepting patients
Massey Cancer Center
Virginia Commonwealth University (VCU Health)
Richmond, VA
  • Accepting patients
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
  • Accepting patients
Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.